RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
Fecha de publicación:
14/01/2025
Fuente: FierceBiotech
With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.